Pfizer Aims To Have First PD-1 Inhibitor Approved In Early NMIBC Setting

 
• By Alaric DeArment

The drug maker announced positive topline Phase III results for its subcutaneous PD-1 inhibitor sasanlimab in first-line, BCG-naïve non-muscle invasive bladder cancer combined with BCG.

Bladder cancer medical concept as an anatomical organ symbol with microscopic malignant cells spreading in the human body as a health care 3D illustration.

More from Immuno-oncology

More from Scrip